Company news: Novo Nordisk

Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir.

August 4, 2011

8:25 pm

Novo Nordisk reported first-half gains in operating profit of 13%, along with sales growth of 11% in local currencies driven by Victoza, NovoRapid and Levemir. Victoza sales were up 253% to around $444 million while sales of modern insulins were up 10% and North American sales rose 15%.

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.